J.P. Obrecht

674 total citations
32 papers, 460 citations indexed

About

J.P. Obrecht is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, J.P. Obrecht has authored 32 papers receiving a total of 460 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 9 papers in Immunology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in J.P. Obrecht's work include Immune Cell Function and Interaction (5 papers), Cancer Treatment and Pharmacology (5 papers) and Breast Cancer Treatment Studies (4 papers). J.P. Obrecht is often cited by papers focused on Immune Cell Function and Interaction (5 papers), Cancer Treatment and Pharmacology (5 papers) and Breast Cancer Treatment Studies (4 papers). J.P. Obrecht collaborates with scholars based in Switzerland, Italy and Germany. J.P. Obrecht's co-authors include R. Obrist, W. F. Jungi, Christian Ludwig, R. Landmann, F. Cavalli, M. Castiglione, Beat Thürlimann, Aron Goldhirsch, Markus Borner and M. Bacchi and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Annals of Oncology.

In The Last Decade

J.P. Obrecht

32 papers receiving 434 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J.P. Obrecht Switzerland 12 175 152 118 86 81 32 460
Y Okudaira Japan 13 134 0.8× 88 0.6× 61 0.5× 112 1.3× 102 1.3× 45 532
V. K. Vaitkevicius United States 10 164 0.9× 49 0.3× 55 0.5× 57 0.7× 66 0.8× 22 440
Alejandro Andicoechea Spain 15 232 1.3× 211 1.4× 105 0.9× 34 0.4× 58 0.7× 26 492
Gaosheng Huang China 13 122 0.7× 68 0.4× 66 0.6× 90 1.0× 29 0.4× 35 432
Éva Pócsik Hungary 13 158 0.9× 78 0.5× 344 2.9× 48 0.6× 24 0.3× 30 612
Anne‐Marie Houllier France 11 205 1.2× 152 1.0× 51 0.4× 21 0.2× 55 0.7× 15 485
M Koike Japan 12 201 1.1× 43 0.3× 58 0.5× 207 2.4× 37 0.5× 30 457
Shuji Nambu Japan 9 112 0.6× 79 0.5× 98 0.8× 38 0.4× 33 0.4× 18 484
Tomoaki Akagi Japan 9 129 0.7× 136 0.9× 131 1.1× 207 2.4× 47 0.6× 27 443
Hiroshi Akutagawa Japan 12 159 0.9× 49 0.3× 85 0.7× 54 0.6× 156 1.9× 33 505

Countries citing papers authored by J.P. Obrecht

Since Specialization
Citations

This map shows the geographic impact of J.P. Obrecht's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J.P. Obrecht with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J.P. Obrecht more than expected).

Fields of papers citing papers by J.P. Obrecht

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J.P. Obrecht. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J.P. Obrecht. The network helps show where J.P. Obrecht may publish in the future.

Co-authorship network of co-authors of J.P. Obrecht

This figure shows the co-authorship network connecting the top 25 collaborators of J.P. Obrecht. A scholar is included among the top collaborators of J.P. Obrecht based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J.P. Obrecht. J.P. Obrecht is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Laffer, U, et al.. (2015). Intraperitoneal Chemotherapy for Gastrointestinal Malignancies. Antibiotics and chemotherapy/Antibiotica et chemotherapia. 40. 26–34. 1 indexed citations
2.
Obrist, R., et al.. (2008). Tumorpatient und Paramedizin: Versuch einer Charakterisierung von Anwendern unkonventioneller Therapieverfahren in der Onkologie*. DMW - Deutsche Medizinische Wochenschrift. 114(9). 323–330. 1 indexed citations
3.
4.
5.
Obrist, R., H. Denz, Christian Ludwig, et al.. (1993). Pharmacokinetics and immunomodulatory effects on monocytes during prolonged therapy with liposomal muramyltripeptide. Biotherapy. 7(1). 1–12. 15 indexed citations
6.
Landmann, R., Christian Ludwig, M. Wesp, et al.. (1992). Prolonged Interferon-γ Application by Subcutaneous Infusion in Cancer Patients: Differential Response of Serum CD14, Neopterin, and Monocyte HLA Class I and II Antigens. Journal of Interferon Research. 12(2). 103–111. 11 indexed citations
7.
Landmann, Régine, M. Wesp, & J.P. Obrecht. (1991). Cytokine Regulation of the Myeloid Glycoprotein CD14. Pathobiology. 59(3). 131–135. 14 indexed citations
8.
Landmann, R., Christian Ludwig, R. Obrist, & J.P. Obrecht. (1991). Effect of cytokines and lipopolysaccharide on CD14 antigen expression in human monocytes and macrophages. Journal of Cellular Biochemistry. 47(4). 317–329. 66 indexed citations
9.
Labéta, Mario O., et al.. (1991). Human b cells express membrane-bound and soluble forms of the cd 14 myeloid antigen. Molecular Immunology. 28(1-2). 115–122. 41 indexed citations
10.
Borner, Markus, U Laffer, R. Obrist, et al.. (1990). Effectiveness and low toxicity of hepatic artery infusion with fluorouracil and mitomycin for metastatic colorectal cancer confined to the liver. Annals of Oncology. 1(3). 227–228. 7 indexed citations
11.
Landmann, R., et al.. (1990). Recombinant interferon γ up-regulates in vivo and down-regulates in vitro monocyte CD14 antigen expression in cancer patients. Cancer Immunology Immunotherapy. 31(5). 292–296. 13 indexed citations
12.
Obrist, R., et al.. (1990). Improved Tolerance of Interferon alpha-2a by Continuous Subcutaneous Infusion. Oncology Research and Treatment. 13(2). 117–122. 4 indexed citations
13.
Pfister, E., et al.. (1988). Randomisierte Doppelblindstudie über die analgetische Wirkung von Caerulein und Morphin bei chronischen Tumorschmerzen. Oncology Research and Treatment. 11(2). 77–80. 2 indexed citations
14.
Alberto, P., W. F. Jungi, P Siegenthaler, et al.. (1988). A phase II study of doxifluridine in patients with advanced breast cancer. European Journal of Cancer and Clinical Oncology. 24(3). 565–566. 7 indexed citations
15.
16.
17.
Hartmann, Dan, et al.. (1982). T-lymphocyte cloning and lymphocyte stimulation as preoperative immunologic parameters in breast-cancer patients. European Journal of Cancer and Clinical Oncology. 18(12). 1401–1401. 3 indexed citations
18.
Kröner, Paul T., J.P. Obrecht, & W. F. Jungi. (1982). Etoposide as single agent and in combination with cis-platinum for malignant lymphomas. Cancer Treatment Reviews. 9. 39–43. 25 indexed citations
19.
Gudat, F, M. Kasper, Gunthild Krey, et al.. (1981). [The diagnostic value of T- and B-rosette formation and the unspecific acid esterase in the differential diagnosis of acute and chronic leukemia].. PubMed. 111(36). 1325–30. 1 indexed citations
20.
Tsuchimoto, T., et al.. (1974). DELETION OF CHROMOSOME 7 IN POLYCYTHAEMIA VERA. The Lancet. 303(7857). 566–566. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Y Okudaira Breakdown of academic impact, for papers by V. K. Vaitkevicius Breakdown of academic impact, for papers by Alejandro Andicoechea Breakdown of academic impact, for papers by Gaosheng Huang Breakdown of academic impact, for papers by Éva Pócsik Breakdown of academic impact, for papers by Anne‐Marie Houllier Breakdown of academic impact, for papers by M Koike Breakdown of academic impact, for papers by Shuji Nambu Breakdown of academic impact, for papers by Tomoaki Akagi Breakdown of academic impact, for papers by Hiroshi Akutagawa
Rankless by CCL
2026